Opioid addiction is a chronic disease, generally driven by a strong and irresistible urge or craving for the intake of opioid drugs and an inability to stop despite negative consequences to health, personal, and professional well-being. Maintenance treatments for opioid addiction are either substitution therapies or abstinence therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine / naloxone combination) are opioid agonists or partial agonists, while abstinence therapies (i.e., naltrexone) are opioid antagonists. With the U.S. market withdrawal of Probuphine (buprenorphine implant) and Bunavail (buprenorphine / naloxone buccal film) in 2020 by their respective marketers owing to commercial decisions, few brands remain for the management of opioid addiction. Nevertheless, the multiple shortcomings of current treatments (e.g., misuse and diversion potential, relapse rates) provide opportunities for drug developers, and it is valuable for drug marketers and developers to understand physicians’ prescribing behavior, the factors influencing treatment decisions, and expected changes in prescribing patterns in the coming year in opioid addiction.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 102 psychiatrists in the United States..
Key companies: Alkermes, Indivior, Orexo.
Key drugs: Methadone, Sublocade, Suboxone Film, Vivitrol, Zubsolv, buprenorphine / naloxone sublingual film (generic), buprenorphine sublingual tablet (generic), naltrexone (generic).
Key insights provided: